Skip to main content
Signal8

NORTHWEST BIOTHERAPEUTICS INC (NWBO)

Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Northwest Biotherapeutics, Inc. logo

Northwest Biotherapeutics, Inc.

OTC:NWBOHealthcare
+2.05%$0.1492
Mkt Cap$270.35M
EV-
Float1.78B
O/S1.81B
VOL5.11M sh
$ Vol$738K
RVOL1.15×
Inst Own0.1%
Net Cash/Sh-
Dilution
Northwest Biotherapeutics, Inc. logoOTC:NWBO$0.1492+2.05%

NORTHWEST BIOTHERAPEUTICS INC (NWBO) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 13 SEC filings.

Shelf registration
S-3 filed Oct 24, 2025, effective Nov 25, 2025
Source: 424B5 filed Jul 31, 2026
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
1 warrant series recorded as outstanding
Most recent offering
Offering, closed Sep 8, 2026
Source: 10-Q filed Nov 13, 2026

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro